Search:

Advanced

Full-text links

                            Title & authors                            Abstract                                                        Similar articles                        Cited by                            Publication types                        MeSH terms                        Substances                                        LinkOut - more resources                

Review

. 2018 Dec;55:89-96.

 doi: 10.1016/j.coi.2018.09.016.Epub 2018 Nov 15.

Bridging the Gap Between Vaccination With Bacille Calmette-Guérin (BCG) and Immunological Tolerance: The Cases of Type 1 Diabetes and Multiple Sclerosis

Giovanni Ristori 1, Denise Faustman 2, Giuseppe Matarese 3, Silvia Romano 4, Marco Salvetti 5

Affiliations 

• PMID: 30447407
 
• DOI: 10.1016/j.coi.2018.09.016

Abstract

At the end of past century, when the prevailing view was that treatment of autoimmunity required immune suppression, experimental evidence suggested an approach of immune-stimulation such as with the BCG vaccine in type 1 diabetes (T1D) and multiple sclerosis (MS). Translating these basic studies into clinical trials, we showed the following: BCG harnessed the immune system to 'permanently' lower blood sugar, even in advanced T1D; BCG appeared to delay the disease progression in early MS; the effects were long-lasting (years after vaccination) in both diseases. The recently demonstrated capacity of BCG to boost glycolysis may explain both the improvement of metabolic indexes in T1D, and the more efficient generation of inducible regulatory T cells, which counteract the autoimmune attack and foster repair mechanisms.

Copyright © 2018 Elsevier Ltd. All rights reserved.

Similar articles

• Proposing BCG Vaccination for Mycobacterium avium ss. paratuberculosis (MAP) Associated Autoimmune Diseases.
  

  Dow CT.Microorganisms. 2020 Feb 5;8(2):212. doi: 10.3390/microorganisms8020212.PMID: 32033287 Free PMC article. Review.
• TNF, TNF inducers, and TNFR2 agonists: A new path to type 1 diabetes treatment.
  

  Faustman DL.Diabetes Metab Res Rev. 2018 Jan;34(1). doi: 10.1002/dmrr.2941. Epub 2017 Sep 29.PMID: 28843039 Review.
• Bacille Calmette-Guérin/DNAhsp65 prime-boost is protective against diabetes in non-obese diabetic mice but not in the streptozotocin model of type 1 diabetes.
  

  da Rosa LC, Chiuso-Minicucci F, Zorzella-Pezavento SF, França TG, Ishikawa LL, Colavite PM, Balbino B, Tavares LC, Silva CL, Marques C, Ikoma MR, Sartori A.Clin Exp Immunol. 2013 Sep;173(3):430-7. doi: 10.1111/cei.12140.PMID: 23692306 Free PMC article.
• Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes.
  

  Huppmann M, Baumgarten A, Ziegler AG, Bonifacio E.Diabetes Care. 2005 May;28(5):1204-6. doi: 10.2337/diacare.28.5.1204.PMID: 15855590 No abstract available.
• The interplay between bacillus Calmette-Guérin and Treg cells and its role to prevent or cure inflammatory diseases.
  

  Lagranderie M, Guyonvarc'h PM.Expert Rev Clin Immunol. 2014 Jun;10(6):741-5. doi: 10.1586/1744666X.2014.909286.PMID: 24837545 Review.